PL2113253T3 - Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionce - Google Patents
Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionceInfo
- Publication number
- PL2113253T3 PL2113253T3 PL08008292T PL08008292T PL2113253T3 PL 2113253 T3 PL2113253 T3 PL 2113253T3 PL 08008292 T PL08008292 T PL 08008292T PL 08008292 T PL08008292 T PL 08008292T PL 2113253 T3 PL2113253 T3 PL 2113253T3
- Authority
- PL
- Poland
- Prior art keywords
- tumour
- hla
- vaccines
- molecules
- class
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 210000000265 leukocyte Anatomy 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08008292A EP2113253B1 (en) | 2008-04-30 | 2008-04-30 | Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2113253T3 true PL2113253T3 (pl) | 2010-09-30 |
Family
ID=39643855
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08008292T PL2113253T3 (pl) | 2008-04-30 | 2008-04-30 | Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionce |
| PL09005725T PL2111867T3 (pl) | 2008-04-24 | 2009-04-23 | Nowe formulacje zawierające peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów (HLA) klasy I i II do zastosowania w szczepionkach |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09005725T PL2111867T3 (pl) | 2008-04-24 | 2009-04-23 | Nowe formulacje zawierające peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów (HLA) klasy I i II do zastosowania w szczepionkach |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9289478B2 (pl) |
| EP (2) | EP2113253B1 (pl) |
| JP (1) | JP5717268B2 (pl) |
| CN (1) | CN105749285A (pl) |
| AT (2) | ATE462442T1 (pl) |
| AU (1) | AU2009201589C1 (pl) |
| BR (1) | BRPI0900798A8 (pl) |
| CA (1) | CA2665510C (pl) |
| CY (1) | CY1110178T1 (pl) |
| DE (1) | DE602008000891D1 (pl) |
| DK (2) | DK2113253T3 (pl) |
| EA (1) | EA017492B1 (pl) |
| ES (2) | ES2342506T3 (pl) |
| HR (2) | HRP20100354T1 (pl) |
| MX (1) | MX2009004468A (pl) |
| NZ (1) | NZ576423A (pl) |
| PL (2) | PL2113253T3 (pl) |
| PT (2) | PT2113253E (pl) |
| RS (1) | RS52115B (pl) |
| SI (2) | SI2113253T1 (pl) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
| US8435507B2 (en) | 2004-08-19 | 2013-05-07 | University Of Maryland | Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer |
| BRPI0813621A2 (pt) | 2007-07-27 | 2017-05-09 | Immatics Biotechnologies Gmbh | imunoterapia contra tumores neuronais e cerebrais |
| UA103751C2 (ru) | 2007-07-27 | 2013-11-25 | Имматикс Биотекнолоджис Гмбх | Иммуногенный пептид для иммунотерапии |
| CY1112212T1 (el) * | 2008-04-24 | 2015-12-09 | Immatics Biotechnologies Gmbh | Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια |
| PT2119726E (pt) * | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| US20110223188A1 (en) * | 2008-08-25 | 2011-09-15 | Solomon Langermann | Targeted costimulatory polypeptides and methods of use to treat cancer |
| EP2927240A1 (en) | 2008-08-25 | 2015-10-07 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| AU2016204708B2 (en) * | 2008-10-01 | 2018-02-22 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
| PT2172211E (pt) * | 2008-10-01 | 2015-03-09 | Immatics Biotechnologies Gmbh | Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer |
| AU2014271235B2 (en) * | 2008-10-01 | 2017-03-02 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
| GB201019331D0 (en) | 2010-03-19 | 2010-12-29 | Immatics Biotechnologies Gmbh | Methods for the diagnosis and treatment of cancer based on AVL9 |
| AU2015200751B2 (en) * | 2010-03-19 | 2016-11-10 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| CN103547283A (zh) * | 2010-12-14 | 2014-01-29 | 伊玛提克斯生物技术有限公司 | 前列腺相关抗原分子来源的人类白细胞抗原结合肽及其使用方法 |
| WO2013041542A1 (en) * | 2011-09-19 | 2013-03-28 | Alf Lamprecht | Pharmaceutical formulations comprising spherolyophilisates of biological molecules |
| WO2013133405A1 (ja) | 2012-03-09 | 2013-09-12 | オンコセラピー・サイエンス株式会社 | ペプチドを含む医薬組成物 |
| CN110123763A (zh) | 2012-06-21 | 2019-08-16 | 法斯瑞斯公司 | 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法 |
| TWI636065B (zh) | 2013-08-05 | 2018-09-21 | 伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| MX392028B (es) | 2015-05-13 | 2025-03-04 | Agenus Inc | Vacunas para el tratamiento y prevención del cáncer. |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| JP2018518956A (ja) * | 2015-06-19 | 2018-07-19 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 免疫療法で使用するための新規ペプチドおよびペプチド組み合わせおよび膵臓がんおよびその他のがんに対して使用するためにスキャフォールドを作製する方法 |
| GB2544843B (en) * | 2015-07-14 | 2022-08-03 | Professional Compounding Centers Of America Pcca | Poloxamer-based intralesional injections for the delivery of chemotherapeutic agents |
| RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| US10738100B2 (en) | 2017-01-27 | 2020-08-11 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| MA47367B1 (fr) * | 2017-01-27 | 2023-06-28 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
| SG10202108122YA (en) | 2017-01-27 | 2021-09-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| AU2018348165B2 (en) | 2017-10-10 | 2025-09-04 | Seattle Project Corp. | Neoantigen identification using hotspots |
| JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| TW202012430A (zh) | 2018-04-26 | 2020-04-01 | 美商艾吉納斯公司 | 熱休克蛋白質－結合之胜肽組成物及其使用方法 |
| FR3087448B1 (fr) | 2018-10-23 | 2023-10-13 | Pdc Line Pharma | Lignee pdc modifiee pour secreter une cytokine |
| CN115697374A (zh) * | 2020-05-12 | 2023-02-03 | 得克萨斯州大学系统董事会 | 用于治疗胶质母细胞瘤的方法 |
| DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| EP4472659A1 (en) | 2022-02-03 | 2024-12-11 | CeCaVa GmbH & Co. KG | Co-vaccination with cd4 and cd8 antigens |
| EP4410767B1 (de) | 2023-02-03 | 2025-10-01 | Röhm GmbH | Nachhaltiges c3 verfahren mit integrierter erzeugung von rohstoffen |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6045796A (en) * | 1992-12-17 | 2000-04-04 | Anergen, Inc. | Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| DK2275119T3 (da) * | 1995-07-27 | 2013-11-11 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US5861483A (en) * | 1996-04-03 | 1999-01-19 | Pro-Neuron, Inc. | Inhibitor of stem cell proliferation and uses thereof |
| US20030162711A1 (en) * | 1996-04-24 | 2003-08-28 | Soren Bjorn | Pharmaceutical formulation |
| US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| DE19917195B4 (de) | 1999-04-16 | 2006-09-28 | Immatics Biotechnologies Gmbh | Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor |
| US6897288B1 (en) * | 1999-10-19 | 2005-05-24 | Ludwig Institute For Cancer Research | Mage-A12 antigenic peptides and uses thereof |
| CA2386088A1 (en) * | 1999-10-19 | 2001-04-26 | Ludwig Institute For Cancer Research | Mage-a12 antigenic peptides and uses thereof |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| WO2004000347A1 (en) * | 2002-06-21 | 2003-12-31 | Novo Nordisk A/S | Stabilised solid compositions of factor vii polypeptides |
| EP2181595A1 (en) * | 2002-08-16 | 2010-05-05 | Yeda Research And Development Company Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
| EP1617804A4 (en) * | 2003-04-11 | 2007-07-25 | Antigenics Inc | IMPROVED VACCINE BASED ON HEAT SHOCK PROTEINS AND IMMUNOTHERAPIES |
| AR048098A1 (es) * | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| US20080125361A1 (en) * | 2004-11-12 | 2008-05-29 | Novo Nordisk A/S | Stable Formulations Of Peptides |
| EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| ATE512160T1 (de) | 2005-04-26 | 2011-06-15 | Immatics Biotechnologies Gmbh | T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen |
| PL1806358T3 (pl) * | 2005-09-05 | 2010-08-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II |
| ES2330013T3 (es) | 2005-09-05 | 2009-12-03 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas. |
| WO2007028753A2 (de) | 2005-09-09 | 2007-03-15 | Basf Aktiengesellschaft | Fungizide mischungen auf der basis von triazolen |
| WO2007146668A2 (en) * | 2006-06-06 | 2007-12-21 | University Of Massachusetts | Use of imp3 as a prognostic marker for cancer |
| PT2119726E (pt) * | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| PT2172211E (pt) * | 2008-10-01 | 2015-03-09 | Immatics Biotechnologies Gmbh | Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer |
-
2008
- 2008-04-30 DE DE602008000891T patent/DE602008000891D1/de active Active
- 2008-04-30 DK DK08008292.8T patent/DK2113253T3/da active
- 2008-04-30 ES ES08008292T patent/ES2342506T3/es active Active
- 2008-04-30 SI SI200830038T patent/SI2113253T1/sl unknown
- 2008-04-30 AT AT08008292T patent/ATE462442T1/de active
- 2008-04-30 PL PL08008292T patent/PL2113253T3/pl unknown
- 2008-04-30 PT PT08008292T patent/PT2113253E/pt unknown
- 2008-04-30 EP EP08008292A patent/EP2113253B1/en active Active
-
2009
- 2009-04-23 EP EP09005725A patent/EP2111867B1/en active Active
- 2009-04-23 PL PL09005725T patent/PL2111867T3/pl unknown
- 2009-04-23 AU AU2009201589A patent/AU2009201589C1/en not_active Ceased
- 2009-04-23 NZ NZ576423A patent/NZ576423A/en not_active IP Right Cessation
- 2009-04-23 JP JP2009104886A patent/JP5717268B2/ja active Active
- 2009-04-23 SI SI200930119T patent/SI2111867T1/sl unknown
- 2009-04-23 US US12/428,893 patent/US9289478B2/en active Active
- 2009-04-23 PT PT09005725T patent/PT2111867E/pt unknown
- 2009-04-23 CN CN201610085112.0A patent/CN105749285A/zh active Pending
- 2009-04-23 AT AT09005725T patent/ATE526979T1/de active
- 2009-04-23 RS RS20110588A patent/RS52115B/en unknown
- 2009-04-23 ES ES09005725T patent/ES2374138T3/es active Active
- 2009-04-23 DK DK09005725.8T patent/DK2111867T3/da active
- 2009-04-23 EA EA200900487A patent/EA017492B1/ru not_active IP Right Cessation
- 2009-04-24 MX MX2009004468A patent/MX2009004468A/es active IP Right Grant
- 2009-04-24 CA CA2665510A patent/CA2665510C/en not_active Expired - Fee Related
- 2009-04-24 BR BRPI0900798A patent/BRPI0900798A8/pt not_active Application Discontinuation
-
2010
- 2010-06-09 CY CY20101100508T patent/CY1110178T1/el unknown
- 2010-06-28 HR HR20100354T patent/HRP20100354T1/hr unknown
-
2011
- 2011-12-21 HR HR20110965T patent/HRP20110965T1/hr unknown
-
2012
- 2012-01-09 US US13/346,197 patent/US9283267B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2111867T3 (pl) | Nowe formulacje zawierające peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów (HLA) klasy I i II do zastosowania w szczepionkach | |
| PL1922334T3 (pl) | Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów HLA i związana z nimi szczepionka przeciwnowotworowa | |
| EA200800677A1 (ru) | Опухолеассоциированные пептиды, беспорядочно связывающиеся с молекулами класса ii человеческого лейкоцитарного антигена (hla) | |
| SI1794190T1 (sl) | Imunogeni T-pomagalni epitopi iz humanih tumornih antigenov in imunoterapevtski postopki, ki uporabljajo navedene epitope | |
| UA104572C2 (ru) | Новые композиции опухолеассоциированных пептидов, которые связываются с молекулами i или ii класса лейкоцитарного антигена человека (hla) для разработки вакцин | |
| CY1112212T1 (el) | Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια |